The results of a small study suggest that the sooner COVID-19 patients start a pulmonary rehabilitation programme after being taken off ventilators, the better the improvement in walking and breathing capabilities, and muscle gain. Despite significant improvements, the average 3 weeks of rehabilitation was not enough for a full recovery [1].
Patients with severe COVID-19 sometimes spend weeks in intensive care on ventilators. As a result, they may suffer from multiple physical (pulmonary and extra‐pulmonary), emotional, and social limitations, which necessitate a comprehensive, interdisciplinary pulmonary rehabilitation programme. PhD student Yara Al Chikhanie (Grenoble Alps University, France) studied the impact of COVID-19 and the effect of pulmonary rehabilitation. Included in the study were 19 patients with a mean age of 71. Each patient had at least 1 comorbidity. Patients spent on average 26 days in intensive care and 13 days in the pulmonary ward before transfer to a French rehabilitation centre.
A 6-minute walk test (6MWT) was used to evaluate the weekly progress of these patients. Most were still unable to walk when they arrived at the rehabilitation centre. At the end of the rehabilitation (21±8 days) the 6MWT increased from 120±141 m to 337±145 m. This was a significant gain but still a serious impairment, as patients reached only 43±24% of the normal predicted distance. Measurement of oxygen saturation during the 6MWT revealed that most patients still had a reduced oxygen saturation (SpO2 85±6%), although patients had no perceived dyspnoea.
The most important finding of the study was that patients who were admitted to pulmonary rehabilitation shortly after leaving intensive care progressed faster than those who spent a longer period in the pulmonary ward. The sooner rehabilitation started and the longer it lasted, the faster and better the improvement in patients’ walking and breathing capacities and muscle gain. Patients who started rehabilitation in the week after being taken off their ventilators progressed faster than those who were admitted after 2 weeks. Despite the significant improvement, the average period of 3 weeks in rehabilitation was not enough to recover completely. Walking ability improved until the end of the rehabilitation. Participants also had a significant recovery of lung volumes and capacities, and leg and handgrip strength, but post-traumatic stress disorder was not resolved in concerned patients.
“These findings suggest that doctors should start rehabilitation as soon as possible and that patients should try to spend as little time as possible being inactive,” Ms Al Chikhanie concluded. ERS President Prof. Thierry Troosters (KU Leuven, Belgium) commented that the results of this study are perfectly in line with a recent statement of the ERS in which a tailored rehabilitation is recommended for COVID-19 patients after the in-hospital phase [2].
- Al Chikhanie Y, et al. New insights into determinants of patient-reported outcomes in chronic respiratory diseases. LBA PA938, ERS International Virtual Congress 2020, 7-9 Sept.
- Spruit MA, et al. Eur Resp J 2020. DOI: 1183/13993003.02197-2020.
Posted on
Previous Article
« Listening to Mozart has a beneficial effect on epilepsy Next Article
Treatment according to genotype: The future of asthma therapy? »
« Listening to Mozart has a beneficial effect on epilepsy Next Article
Treatment according to genotype: The future of asthma therapy? »
Table of Contents: ERS 2020
Featured articles
COVID-19 and the Lung
COVID-19 infections: Bronchoscopy provides additional diagnostic certainty
COVID-19 vaccines: An ongoing race
COVID-19: What is the risk of reinfection?
COVID-19 App: The Dutch experience
Secondary pulmonary fibrosis: a possible long-term effect of severe COVID-19
COVID-19 survivors benefit from structured follow-up
Early pulmonary rehabilitation post-COVID-19 aids recovery
Asthma – What's New
Mild asthma: A fundamental change in management
Dupilumab shows long-term efficacy in asthma patients
Severe asthma: Oral corticosteroids maintenance therapy associated with toxicity
First-in-class tyrosine kinase inhibitor shows promise in severe asthma
Predicting individual effectiveness of biologics in severe asthma
IL-5 antagonist showed efficacy in chronic rhinosinusitis with nasal polyps
Treatment according to genotype: The future of asthma therapy?
COPD – The Beat Goes On
The role of chronic symptoms as early biomarkers of COPD development
Urgent call for studies in COPD patients aged 40-60 years
Nasal high-flow therapy: a novel treatment option for hypercapnic COPD patients
Exacerbation history is a reliable predictor of future exacerbations
Singing training effective as physical rehabilitation in COPD
Current prediction tools underestimate exacerbation risk of severe COPD patients
Exercise and Sleep: From Impaired Function to New Therapeutic Strategies
CPAP withdrawal has negative consequences for sleep apnoea patients
Physical activity improves AHI in sleep apnoea patients
The Tobacco Epidemic: From Vaping to Cannabis
Poly-use of nicotine products and cannabis: a deadly combination
E-cigarettes: A source of chronic lung inflammation
Social smoking: Do not underestimate the risks
Chronic Cough – State of the Art
LEAD study shows multiple phenotypes in many chronic cough patients
First-in-class P2X3 receptor antagonist shows promise for chronic cough treatment
Lung Cancer Detection
Lung cancer screening: Most patients not eligible 1-2 years prior to diagnosis
Distinct changes in lung microbiome precede clinical diagnosis of lung cancer
Best of Posters
Smartphone-based cough detection helpful in predicting asthma deterioration
Reduced lung function associated with cognitive decline in the elderly
Longer hospital stay and fewer transplants for frail ILD patients
Related Articles
August 17, 2022
Thoracic ultrasound: a new diagnostic imaging tool in RA-ILD?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com